|
|
||
|
|
Pittsburgh, PA – July 15, 2004 -
Automated Cell, Inc. announces the addition of Louis M. Weiner, M.D. to
its Scientific Advisory Board. Dr. Weiner is Chairman, Department of Medical
Oncology and the G. Morris Dorrance, Jr. Professor of Medical Science at Fox
Chase Cancer Center. Dr.
Weiner’s research centers on the use of antibody-based molecules to target
tumors, with an emphasis on understanding the principles of tumor targeting
and the use of antibodies to initiate host immune-mediated tumor lysis. He has been at the forefront of efforts to
develop antibody-based therapies of human cancer. Dr. Weiner has been a pioneer in the use of antibody
engineering to improve selective tumor targeting and to manipulate
antibody-directed immune effector functions.
Dr. Weiner received his MD from Mount Sinai School of Medicine in 1977
and his BA with Honors in Biology from the University of Pennsylvania in
1973. Dr. Weiner joins Kenneth A. Foon, M.D., the Co-Director of
Biological Therapy and Hematologic Malignancy Program at the University of
Pittsburgh Cancer Institute and the former Director of Clinical Development
for Oncology at Abgenix, Inc.; John Kirkwood, M.D., Director of the Melanoma
Center and the Chief of Medical Oncology at the University of Pittsburgh
Cancer Institute; Charles
Cantor, Ph.D., CSO, Sequenom and Joel Greenberger, M.D., Assistant Director,
University of Pittsburgh Cancer Institute. Automated
Cell is a drug discovery company focused on the development of therapeutic
antibodies for the treatment of cancer. Automated Cell is currently
developing an internal drug pipeline of antibodies to treat cancer and will
commercialize these novel therapeutic antibodies in partnership with
pharmaceutical and biotechnology companies. For more
information, please contact: Kevin Sullivan at 412-826-5203 or ksullivan@automatedcell.com. Copyright © 2004, Automated Cell, Inc. |
|
|
|
|
|
|
|
|
|
